NEW YORK, Aug. 8, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Depomed, Inc. ("Depomed" or the "Company") (NASDAQ: DEPO). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/depo.
The investigation concerns whether Depomed and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On August 7, 2017, after-market hours, Depomed revealed that it had received notice from the U.S. Senate Committee on Homeland Security and Governmental Affairs and from the Office of the Attorney General of Maryland and the U.S. Department of Justice requesting information relating to the promotion of opioids. Following this news, Depomed stock dropped sharply during intraday trading on August 8, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Depomed, you can assist this investigation by visiting the firm's site: www.bgandg.com/depo. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC